JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, today announced positive results from a Phase 2a trial of BL-1020, a GABA-enhanced antipsychotic. BL-1020 showed statistically significant efficacy with no significant change in weight and no increase in extrapyramidal symptoms at study completion. The Company had announced positive interim results from the trial in October 2007.
